








**a****b****c****d****e****f****g**

**Figure S8. a** Representative western blot illustrating expression of endogenous PKM2 and exogenous flag-tagged WT, T328A, and T328E PKM2 in U87 cells used for survival analyses in Figures 6A, 6B and 6D and Supplemental Figures 6C-G. Neo, neomycin vector. **b** Representative western blot showing expression of endogenous CtIP and exogenous flag-tagged WT and T126E CtIP in cells used for survival analyses in Figure 6C. **c** U251 shCtrl or shPKM2 cells, and shPKM2 cells expressing shRNA-resistant WT, T328A, or T328E PKM2 were incubated with the indicated concentrations of olaparib. Cell viability was determined by trypan blue staining 48 h after treatment. Data are the relative mean fraction of surviving cells  $\pm$  SE (n = 3). **d** U87 shCtrl or shPKM2 cells, and shPKM2 cells expressing shRNA-resistant WT or T328A PKM2, were irradiated as indicated. The number of viable cells was determined by trypan blue 5 d later. Data are presented as the relative mean fraction of surviving cells  $\pm$  SE (n = 3). **e** U87 shCtrl and shPKM2 cells were incubated with the indicated concentrations of CPT-11. Cell viability was determined 72h later and used to generate the IC<sub>50</sub> for each cell line. **f** U87 shCtrl and shPKM2 cells, and shPKM2 cells expressing shRNA-resistant WT or T328A PKM2, were treated with 10 nM CPT-11. The number of viable cells was determined by trypan blue staining at the indicated time points. Data are the relative mean fraction of surviving cells  $\pm$  SE (n = 3). **g** U87 shCtrl or shPKM2 cells, and shPKM2 cells expressing shRNA-resistant WT or T328A PKM2, were treated with H<sub>2</sub>O<sub>2</sub> as indicated. Cell viability was determined 72h later. \*, *P* <0.05.